Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
563 stopped studies mapped to Malignant Pancreatic Neoplasm and descendants · 93% state a reason
Over the 563 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03374852 | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced… | Phase 2 | withdrawn | Dec 15, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | PI Left institution on 8/6/2018 and study has been final reported with IRB. Never opened to accrual | Investigator |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or… | Phase 2 | terminated | Aug 1, 2018 | M.D. Anderson Cancer Center | Lack of Efficacy | Efficacy / futility |
| NCT05940844 | Study of OB-002 in Patients With Refractory Metastatic Cancer | Phase 1 | withdrawn | Jul 11, 2023 | Orion Biotechnology Polska Sp. z o.o. | study terminated due to changes in the drug development plan | Other (stated, no rule matched) |
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Phase 1 | terminated | Feb 21, 2023 | Mirati Therapeutics Inc. | Formulation challenges | Other (stated, no rule matched) |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT04476537 | RNA Precision Oncology in Advanced Pancreatic Cancer(HIPPOCRATES) | N/A | terminated | Jul 20, 2020 | Columbia University | Lack of feasibility | Other (stated, no rule matched) |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT05494866 | A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage…(IntenSify) | Phase 1 | terminated | Aug 10, 2022 | German Cancer Research Center | lack of efficacy paired with high toxicity | Safety / toxicity |
| NCT03520790 | Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer | Phase 1 | terminated | May 11, 2018 | Dana-Farber Cancer Institute | Phase II was not pursued due to futility based on the results of the NAPOLI-3 therapeutic clinical… | Efficacy / futility |
| NCT04976660 | TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors | Phase 1 / Phase 2 | withdrawn | Jul 26, 2021 | Tarus Therapeutics, Inc. | Tarus is conducting clinical development under a single IND, specifically IND for TT-10 (PORT-6).… | Other (stated, no rule matched) |
| NCT00881621 | Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer | Phase 2 | terminated | Apr 15, 2009 | Georgetown University | slow enrollment | Enrollment / accrual |
| NCT03563144 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | Phase 2 | withdrawn | Jun 20, 2018 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT05523154 | "Answers in Hours" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile… | N/A | terminated | Aug 31, 2022 | Mayo Clinic | lack of funding | Funding |
| NCT03822936 | Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas…(PIOPPO) | Phase 2 | terminated | Jan 30, 2019 | CNAO National Center of Oncological Hadrontherapy | The study was early closed due to low accrual in August 2022. | Enrollment / accrual |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small… | Phase 1 | terminated | Nov 30, 2022 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT03736720 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory… | Phase 2 | terminated | Nov 9, 2018 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT02672917 | Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen… | Phase 1 | terminated | Feb 3, 2016 | BioNTech Research & Development, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04916236 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers(SHERPA) | Phase 1 | terminated | Jun 7, 2021 | The Netherlands Cancer Institute | Due to a lack of safety and efficacy. | Safety / toxicity |
| NCT06206876 | FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | withdrawn | Jan 16, 2024 | Roswell Park Cancer Institute | never opened | Other (stated, no rule matched) |
| NCT02671890 | Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or… | Phase 1 | terminated | Feb 2, 2016 | Mayo Clinic | lack of funding | Funding |
| NCT04807972 | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV)… | Phase 1 | terminated | Mar 19, 2021 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT05861336 | GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally…(OVERPASS) | Phase 2 | withdrawn | May 16, 2023 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | No patients enrolled | Enrollment / accrual |
| NCT05546411 | A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | Phase 2 | terminated | Sep 19, 2022 | Kimberly Perez, MD | Novartis, the drug manufacturer of NIS793, notified Dana Farber Cancer Institute that they are… | Drug supply |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT03329248 | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated… | Phase 1 / Phase 2 | terminated | Nov 1, 2017 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT04136769 | Preoperative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for…(PREVADER) | N/A | terminated | Oct 23, 2019 | Ulrich Ronellenfitsch, MD | Substantial delays in recruitment | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT01318642 | Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas | Phase 2 | terminated | Mar 18, 2011 | NantBioScience, Inc. | NCT01318642: Planned independent DMC Interim review: ended for futility | Efficacy / futility |
| NCT03512756 | A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic… | Phase 2 / Phase 3 | terminated | May 1, 2018 | Tyme, Inc | Sponsor's decision | Sponsor / business decision |
| NCT03960060 | A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid…(CAR) | Phase 1 | terminated | May 22, 2019 | Shanghai PerHum Therapeutics Co., Ltd. | Adjustment of study strategy | Sponsor / business decision |
| NCT05056805 | An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of… | N/A | withdrawn | Sep 27, 2021 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine… | Phase 1 / Phase 2 | withdrawn | Nov 9, 2022 | University of Chicago | 0 enrollment | Enrollment / accrual |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03592264 | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 19, 2018 | OBI Pharma, Inc | Little evidence of clinical activity in tumor types enrolled | Enrollment / accrual |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and… | Phase 2 | terminated | Jul 5, 2017 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT04536077 | Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | Phase 2 | terminated | Sep 2, 2020 | Washington University School of Medicine | Celldex decision | Other (stated, no rule matched) |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in… | Phase 1 / Phase 2 | terminated | Dec 24, 2020 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT04517448 | Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy(EQLVCPAL) | — | terminated | Aug 18, 2020 | Centre Hospitalier de la côte Basque | End of recruitment - Number of required subjects enrolled | Enrollment / accrual |
| NCT03716596 | SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent…(CISPD-2) | Phase 1 | terminated | Oct 23, 2018 | Second Affiliated Hospital, Zhejiang University, School of Medicine | The effect of the regime was not satisfied | Other (stated, no rule matched) |
| NCT02745197 | A Study to See Whether a Nutritional Supplement is Beneficial for Patients With… | Phase 2 | withdrawn | Apr 20, 2016 | University of Alberta | change in concept | Other (stated, no rule matched) |
| NCT05188586 | New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)(NODMED) | N/A | terminated | Jan 12, 2022 | ClearNote Health | enrollment targets not met | Enrollment / accrual |
| NCT03586869 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | Phase 1 / Phase 2 | terminated | Jul 16, 2018 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT06054308 | Mesothelin-targeted CAR-T Cells as a Neo-adjuvant Treatment in Patients With Resectable…(CART) | N/A | withdrawn | Sep 26, 2023 | Chinese University of Hong Kong | Unable to obtain Clinical Trial Certificate due to tech Unable to obtain Clinical Trial Certificate… | Other (stated, no rule matched) |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | Phase 1 / Phase 2 | terminated | Jan 8, 2009 | NantCell, Inc. | Sponsor decision - subjects rolled over to protocol 20101116 | Sponsor / business decision |
| NCT06110598 | CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) | Phase 2 | withdrawn | Oct 31, 2023 | Case Comprehensive Cancer Center | PI left the institution | Investigator |
| NCT06518538 | Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With… | Phase 2 | withdrawn | Jul 24, 2024 | Cornerstone Pharmaceuticals | due to study redesign | Other (stated, no rule matched) |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant… | Phase 1 / Phase 2 | terminated | Oct 3, 2023 | Tango Therapeutics, Inc. | Terminated due to safety | Safety / toxicity |
| NCT02798003 | Food Reward in Cachexia Induced by Acute or Chronic Disease | — | terminated | Jun 14, 2016 | Maastricht University Medical Center | Not feasible to include the needed patients | Other (stated, no rule matched) |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803… | Phase 1 / Phase 2 | terminated | Apr 25, 2017 | NantCell, Inc. | The study was terminated before any dose escalation occurred in order to pursue other studies… | Other (stated, no rule matched) |
| NCT00113256 | Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable… | Phase 2 / Phase 3 | terminated | Jun 7, 2005 | Astex Pharmaceuticals, Inc. | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 29, 2025source: clinicaltrials